NanoString Technologies is a privately held provider of life science tools for translational research and developer of molecular diagnostic products. The company's nCounter Analysis System delivers highly multiplexed, direct profiling of individual molecules in a single reaction without amplification. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/12 | $15,300,000 | Series E |
AllianceBernstein Morgan Stanley Expansion Capital | undisclosed |
